Nicole van de Leuv

Nicole van de Leuv is Head of Legal at IconOVir Bio. Nicole also serves as a Principal at Two River, where she provides legal and operational support to Two River and its portfolio companies. Prior to joining Two River, Nicole was Special Counsel at Cooley LLP, where she focused on mergers and acquisitions and other […]

IconOVir Bio Raises $77 Million in Series A Financing to Develop Next-Generation Oncolytic Viruses to Treat Solid Tumors

Series A financing co-led by Nextech and Vida Ventures with participation from Two River Group, Bellco Capital, Polaris Partners, GV, Wellington Management Company, LLP and Logos Capital IconOVir formed by team behind Kite Pharma, Allogene Therapeutics and Kronos Bio Proprietary oncolytic virus platform based on technology developed at Salk Institute under the leadership of renowned […]

Clodagh O’Shea, Ph.D.

Clodagh O’Shea is the Scientific Founder of IconOVir Bio and Chair of IconOVir’s Scientific Advisory Board. She is also the Wicklow Capital Chair and Professor of Molecular and Cell Biology at the Salk Institute, a Howard Hughes Medical Institute Faculty Scholar, Allen Distinguished Investigator, Adjunct Professor at UCSD and Director of the Redesigning Biology and […]

Owen Witte, M.D.

Owen received his undergraduate degree from Cornell and his M.D. from Stanford University. He completed postdoctoral research at MIT, then joined the faculty at UCLA where he was recently appointed as University Professor by the University of California Board of Regents, an honor reserved for scholars of the highest international distinction. Owen is also a […]

William Kaelin, M.D.

William Kaelin

Dr. Kaelin is the Sidney Farber Professor in the Department of Medicine at the Dana-Farber Cancer Institute and at the Brigham and Women’s Hospital, Harvard Medical School. Dr. Kaelin was awarded the 2019 Nobel Prize for Physiology or Medicine, with co-recipients Sir Peter J. Ratcliffe and Dr. Gregg L. Semenza, for discoveries related to the […]

Jakob Loven, Ph.D.

Jakob Loven, Ph.D., is a Managing Partner at Nextech Invest with over 20 years of experience in cancer research and translational medicine. An accomplished oncology-focused entrepreneur and life science venture capitalist, Jakob has extensive experience in creating, launching and building early stage therapeutic-focused biotechnology companies and was a co-founder of Relay Therapeutics (NASDAQ: RLAY) and […]

Helen Kim

Helen S. Kim is a Managing Director of Vida Ventures, a life sciences focused venture capital firm. Ms. Kim has over 28 years of experience in leadership roles in biotechnology. Most recently, Ms. Kim was a Partner at The Column Group. Prior, Ms. Kim served as Executive Vice President of Business Development at Kite Pharma, […]

David Chang, M.D., Ph.D.

David D. Chang is a co-founder and Chairman of the Board of Directors of IconOVir Bio. He is a co-founder and currently serves as the President and Chief Executive Officer of Allogene Therapeutics, Inc. (ALLO), a clinical stage biotechnology company focused on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies […]

Juli DeGraw

Juli is the Vice President of CMC and Product Development at IconOVir Bio. Prior to IconOVir she was Managing Director of the Life Science Consulting Group, L.L.C. supporting CMC due diligence, IND packages and GMP manufacturing strategies for clients including Dr. Clodagh O’Shea at the Salk Institute for Biological Studies. Juli joined the Department of Oncology […]

Michael Lyman

Michael Lyman is the Vice President of Discovery Research at IconOVir Bio. Prior to joining IconOVir, Michael was the Director of Translational Research at the Salk Institute of Biological Studies where he led a translational research team working with Clodagh O’Shea to develop a pipeline of novel virus-based therapies including oncolytic viruses. Before going to the […]